UK Myeloma expert from Oxford, Professor Karthik Ramasamy, Clinical Director, SACT Clinical Reference Group for GenesisCare, based at their centre in Oxford, is leading the SECURE study, one of ...
A combination of genetic tests for a "very complex" blood cancer could accurately predict if the disease is likely to return within 18 months of treatment, a study has found. This method picks up ...
Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say researchers from the University of Leeds and The Institute of Cancer Research. Up to ...
In a clinical trial, relapsed patients treated with carfilzomib in combination with lenalidomide and dexamethasone lived 8.7 months longer without disease progression compared with lenalidomide and ...
Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma, according to findings from the phase III AQUILA trial presented at the ...
MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results